文献速递肝病

PPAR激动剂作为原发性胆汁性胆管炎二线治疗疗效比较:系统综述与网状Meta分析

Comparative effectiveness of peroxisome proliferator-activated receptor agonists as second-line therapies for primary biliary cholangitis: A systematic review and network meta-analysis.
PubMed 文献 · Hepatology · 2025-07-15

本研究通过系统综述与网状Meta分析评估PPAR激动剂作为原发性胆汁性胆管炎二线治疗的疗效与安全性,纳入8项随机对照试验共727例参与者。所有药物在生化应答和ALP正常化方面均优于安慰剂,贝特类在主要结局排名最高。因不良事件停药少见,长期安全性仍需进一步研究。

要点

  • PPAR激动剂作为二线治疗在生化应答和ALP正常化上均优于安慰剂
  • 贝特类在主要结局生化应答中排名最高
  • 贝特类和seladelpar在ALP正常化中排名最高

核心结论

  • PPAR激动剂是原发性胆汁性胆管炎有效的二线治疗。
  • 治疗排名的差异可能反映结局、人群和药物机制的不同。
  • 在缺乏头对头试验的情况下,网状Meta分析提供了比较疗效的重要信息。

研究设计与样本

  • 系统综述与频率学派网状Meta分析,纳入8项随机对照试验共727例参与者,评估4种PPAR激动剂。
  • 主要结局为生化应答,次要结局为ALP正常化;采用随机效应模型,按基线ALP分层。

主要发现

  • 所有PPAR激动剂在生化应答和ALP正常化方面均优于安慰剂。
  • 贝特类在主要结局(生化应答)中排名最高;贝特类和seladelpar在次要结局(ALP正常化)中排名最高。
  • ALP下降百分比不随基线ALP变化;总胆红素变化在各组间相似;因不良事件停药少见。

关键数值与推荐

  • 主要结局为生化应答,次要结局为ALP正常化。
  • 8项随机对照试验,727例参与者,4种PPAR激动剂。
  • 所有药物在生化应答和ALP正常化上均优于安慰剂。
  • 贝特类主要结局排名最高;贝特类和seladelpar次要结局排名最高。
  • 因不良事件停药少见。

临床怎么用

  • 对于熊去氧胆酸应答不足或不耐受的原发性胆汁性胆管炎患者,PPAR激动剂可作为二线治疗选择。
  • 贝特类和seladelpar在ALP正常化方面排名最高,但需结合患者具体情况选择。
  • 治疗期间需关注不良事件,尽管导致停药的情况少见。

局限性

  • 缺乏头对头试验,比较疗效依赖网状Meta分析间接比较。
  • 需进一步研究确认长期安全性并改进以患者为中心的结局评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Primary biliary cholangitis is a chronic cholestatic liver disease that may progress to cirrhosis and liver failure. For patients with inadequate response or intolerance to ursodeoxycholic acid, peroxisome proliferator-activated receptor (PPAR) agonists have emerged as second-line options. This study assessed the comparative effectiveness and safety of PPAR agonists in primary biliary cholangitis through a systematic review and network meta-analysis. APPROACH AND RESULTS: A systematic review identified randomized controlled trials evaluating PPAR agonists versus ursodeoxycholic acid, with or without placebo. A frequentist network meta-analysis assessed biochemical response (primary outcome) and ALP normalization (secondary outcome). Pairwise meta-analyses were performed for percentage change in ALP and total bilirubin, and adverse events leading to treatment discontinuation. Data were stratified by baseline ALP, and a random-effects model was used. Eight randomized controlled trials (727 participants) evaluating 4 PPAR agonists were included. All agents outperformed placebo in achieving biochemical response and ALP normalization. Bezafibrate ranked highest for the primary outcome; both bezafibrate and seladelpar ranked highest for the secondary outcome. Percentage ALP reduction did not vary by baseline ALP. Total bilirubin changes were similar across arms, and treatment discontinuations due to adverse events were infrequent. CONCLUSIONS: PPAR agonists are effective second-line therapies for primary biliary cholangitis. Treatment ranking differences likely reflect variations in outcomes, populations, and drug mechanisms. In the absence of head-to-head trials, network meta-analysis provides important insights into comparative effectiveness. Further studies are warranted to confirm long-term safety and improve the evaluation of patient-centered outcomes.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Martins A, Khakoo NS, Reddy A, et al. Comparative effectiveness of peroxisome proliferator-activated receptor agonists as second-line therapies for primary biliary cholangitis: A systematic review and network meta-analysis. Hepatology. 2025. PMID: 41052304. doi:10.1097/HEP.0000000000001465

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。